Annual Report

Overview

The report highlights Tanvex's 2024 U.S. FDA marketing authorization for its TX01 biosimilar, alongside continued expansion into CDMO services. Consolidated revenue was NT$34,678 thousand for 2024. Sustainability governance was assigned to the Board, but detailed greenhouse gas, water, and waste information was deferred to a Sustainability Report that had not yet been completed by the Annual Report deadline.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 7 April 2025
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services